pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
309
stories
16h
STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals
stat
16h
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
17h
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
18h
STAT+: Up and down the ladder: The latest comings and goings
stat
19h
STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
stat
1d
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
1d
Capricor’s data clash and a fugitive in the C-suite
stat
1d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
1d
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
1d
AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal
endpoints
1d
Gerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacity
endpoints
1d
STAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuels
stat
1d
STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
stat
1d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
1d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
2d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
2d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
2d
NSF testing new Ph.D. model giving trainees academic and industry experience
stat
2d
STAT+: Hims misled consumers and violated their privacy, FTC alleges in a lawsuit
stat
2d
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
2d
STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more
stat
2d
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
2d
GSK cost-cutting plan includes global layoffs
biospace
3d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
3d
FDA offers updated guidance for generics of weight loss blockbusters
endpoints
3d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
3d
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
3d
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
4d
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
biospace
4d
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
← prev
page 1 of 11
next →
